|
|
||||||||
Section of Molecular Genetics and Microbiology and Institute for Cellular and Molecular Biology, University of Texas, Austin, TX 78712
| Abstract |
|---|
|
|
|---|
gene, positively affects CD8 expression in T cells. Therefore, experiments were performed to determine the effect on T cell development of reduced expression of SATB1. Because homozygous SATB1-null mice do not survive to adulthood due to nonthymus autonomous defects, mice were produced that were homozygous for a T cell-specific SATB1-antisense transgene and heterozygous for a SATB1-null allele. Thymic SATB1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of CD8SP T cells in thymus, spleen, and lymph nodes. Mice were smaller than wild type but generally healthy, and besides a general reduction in cellularity and a slight increase in surface CD3 expression on CD8SP thymocytes, the composition of the thymus was similar to wild type. The reduction in thymic SATB1 does not lead to the variegated expression of CD8-negative single positive thymocytes seen upon deletion of several regulatory elements and suggested by others to reflect failure to activate the CD8 locus. Thus, the present results point to an essential role for SATB1 late in the development and maturation of CD8SP T cells. | Introduction |
|---|
|
|
|---|
Nuclear matrix-associated regions (MARs) are short AT-rich DNA sequences that are widespread throughout the eukaryotic genome and have a great affinity for the nuclear matrix in vitro. MARs have been postulated to mediate chromatin loop formation important for compaction of genomic DNA and also to organize chromatin into units of genomic function (10, 11). MARs are frequently colocalized with enhancers or with the boundaries of genes. Together with the enhancers, several MARs have been suggested to mediate positive or negative regulation of gene expression (12, 13, 14, 15, 16, 17).
The MAR-binding protein, SATB1, expressed predominantly in thymocytes, recognizes an ATC sequence context with high potential for unwinding by base unpairing (18). SATB1 has a MAR-binding domain and an atypical homeodomain, both of which are necessary for recognition of the core-unwinding element within a MAR (19, 20). In addition to the binding sites in the MARs of the IgH gene enhancer (18), SATB1 has been found to interact with the MARs of other Ag receptor and coreceptor genes, including the Ig
, TCR-
, and CD8
genes (14, 17, 21, 22). Consistent with the idea that MAR-binding proteins participate in cell type-specific gene regulation at the level of higher-order chromatin structure, SATB1 was found to bind in vivo to genomic sequences that are tightly associated with the nuclear matrix at the bases of the chromatin loops (23). Recent studies suggest that SATB1 binds to DNA and recruits ATP-dependent chromatin remodeling complexes that modify histone acetylation and nucleosome placement over long distances in the IL-2R
gene (24). The binding of SATB1 to genomic sites mediated the formation of a particular region-specific histone code (25).
Previous studies identified a MAR element (L2a) located
4.5 kb upstream of the mouse CD8
gene that appears to play a role in regulation of the CD8
gene expression (16, 17). A number of enhancers have been described in DNase I hypersensitive regions within the 36-kb interval separating the mouse CD8
and CD8
genes (3, 4, 5, 6, 8), and some interaction has been demonstrated between one of these (E8I) and a 4-kb DNA fragment containing the L2a element (6). Targeted deletion of the 4-kb fragment containing the L2a element leads to abnormal thymocyte development characterized by a large population of thymocytes that never turn on CD8 gene expression, leading to a decrease in thymic and peripheral CD8SP T cell populations (7).
We have shown that the L2a element interacts with the MAR-binding proteins SATB1 and CDP (17). CDP belongs to a family of proteins whose role as a transcriptional repressor has been demonstrated in a number of systems (13, 26, 27). On the basis of our earlier studies of the cell type distributions of SATB1 and CDP and their interaction with the L2a element (16, 17), we hypothesized that SATB1 and CDP play positive and negative roles, respectively, in CD8
gene regulation. We have suggested that binding of SATB1 displaces the CDP repressor from the L2a element and favors CD8
expression, probably by altering chromatin structure and/or allowing the L2a element and nearby CD8
gene to associate with the nuclear matrix (17).
Analysis of SATB1-null mice generated by targeted gene inactivation has demonstrated that the absence of SATB1 results in a severe impairment in T cell development characterized by arrest of thymocyte development at an abnormal DP stage (28). The SATB1-null model is complicated by the finding that although SATB1 is expressed preferentially in the thymus, SATB1-null mice die at
23 wk of age, apparently due to lack of an essential function of SATB1 in nonthymic tissues, including brain. Therefore, to test our hypothesis that SATB1 plays a positive role in CD8 expression in vivo, we have generated mice in which expression of SATB1-antisense transcripts is targeted specifically to T lymphocytes and have bred these with mice heterozygous for a SATB1-null allele. The consequence of reducing thymus and T cell expression of SATB1 expression in these mice is a significant reduction in the percentage of CD8SP T cells present in the thymus and the periphery.
| Materials and Methods |
|---|
|
|
|---|
To make the phCD2VA-SATB1-AS vector used for generating the SATB1-antisense transgenic mice, a 3-kb EcoRI fragment containing the mouse SATB1 cDNA sequence was excised from the pmAT vector (19) and subcloned, in antisense orientation with respect to the promoter, into the EcoRI site of the phCD2VA plasmid (29). phCD2VA is a minigene cassette that contains regulatory sequences of the human CD2 gene, including promoter, locus control region, the first intron of the gene, and two polyadenylation signals found in the 3'-untranslated region. A 15-kb KpnI-XbaI fragment containing the sequence of interest was excised from phCD2VA-SATB1-AS and injected into the pronucleus of (C57BL/6 x DBA/2) F2 single-cell embryos as described by Brinster et al. (30).
Founder animals were identified by Southern hybridization of tail DNA and backcrossed to (C57BL/6 x DBA/2) F2 mice to generate transgenic lines. Heterozygous offspring of the founders (+/Tg) were crossed to generate homozygous mice (Tg/Tg) that were identified by Southern blot analysis by comparing the intensities of the bands representing the transgene and the endogenous gene. Homozygosity was confirmed by outcrossing presumptive Tg/Tg homozygous mice to nontransgenic mice and checking progeny for 100% transmission of the transgene.
Production of SATB1-antisense mice heterozygous for a SATB1-null allele
Generation of the SATB1-knockout (KO) mouse strain has been described previously (28). The targeted allele contains a deletion of the translation start site and the first five exons encoding the first 213 amino acids of SATB1. A neo resistance gene directed opposite to the direction of transcription of SATB1 is present in place of the excised segment. Because mice homozygous for the targeted allele did not survive to breeding age, the targeted allele was maintained by breeding heterozygotes. Homozygous SATB1-antisense transgenic mice were crossed with mice heterozygous for the SATB1-null allele and homozygous for transgene. Fifty percent of the progeny of such backcrosses were homozygous SATB1-antisense and heterozygous for the SATB1-null allele.
Extraction and digestion of DNA from mouse tails
Mouse tails were digested overnight at 55°C in tail buffer (50 mM Tris (pH 8.0), 100 mM EDTA, and 1% SDS) containing 0.15 mg/ml proteinase K (Ambion). Samples were extracted sequentially with phenol, phenol-chloroform (25:24), and chloroform, and the DNA was precipitated with a solution containing 30% polyethylene glycol and 1.5 M NaCl. DNA pellets were recovered and resuspended in 100 µl of TE.
Southern blot analysis
The isolated DNA (12 µg) was digested to completion with EcoRI, and fragments were separated by electrophoresis in a 0.7% agarose gel and transferred to a nylon membrane (micrometer separations (MSI)). Blots were hybridized overnight in Ultrahyb solution (Ambion) with a
500-bp AvaI-BamHI probe (mSATB1cDNA 2170-2695) derived from the pmAT plasmid. The probe was generated by random primer synthesis using a decaprime DNA labeling kit (Ambion). After hybridization, membranes were washed at 55°C with 0.5x standard saline citrate phosphate/EDTA, 0.5% SDS and then with 0.25x standard saline citrate phosphate/EDTA, 0.5% SDS. Blots were briefly air-dried and placed in a cassette for phosphorimaging analysis. Transgene copy number was calculated by comparing the intensity of the characteristic transgene fragment (3.05 kb) with that of the endogenous SATB1 gene (4.07 kb).
Polymerase chain reaction
The tip of each mouse tail was digested with proteinase K (0.1 mg/ml) overnight at 55°C in tail PCR buffer (50 mM KCl, 10 mM Tris (pH 8.3), 2.5 mM MgCl2, 0.1 mg/ml gelatin, 0.45% v/v Nonidet P-40, and 0.45% v/v Tween20). Samples were boiled for 5 min, and 10 µl of supernatant were supplied to each PCR. Positive SATB1-KO mice were identified by PCR with primers G7 (5'-GGGTGGGGTGGGATTAGATAAATG-3') and SB1-PC4 (5'-GCTCATAATTTGTCTTGACCAACAG-3'). Thirty cycles of PCR were performed (TaqDNA polymerase kit; Invitrogen Life Technologies) in which each cycle consisted of 30 s of denaturing at 94°C, 1 min of annealing at 64°C, 90 s of elongation at 72°C, and 10 min at 72°C, yielding a 1.2-kb product. For semiquantitative RT-PCR, total RNA was extracted from different tissues using TRI REAGENT (Molecular Research Center). First-strand cDNA was synthesized from 10 µg of mRNA using oligo(dT)1218, Moloney murine leukemia virus reverse transcriptase (Invitrogen Life Technologies), dNTP mix, RNase inhibitor, and 5x first-strand buffer in a final volume of 50 µl. The mixture was incubated sequentially at 37°C for 1 h, 95°C for 5 min, and then cooled to 4°C. An aliquot of this cDNA mixture (5 µl) was used for PCR amplifications using antisense SATB1 gene-specific primers: hCD2-1 (5'-TCCATGTAAATTTGTAGC-3') and SATB1-AS-1 (5'-CTGTAACCCGCCACACTAGTC-3'); and GAPDH primers: GAPDH985 (5'-GTTGCTGTAGCCGTATTCATTGTC-3' and GAPDH427 (5'-CATGTTTGTGATGGGTGTGAACCA-3').
Flow cytometric analysis
Thymocytes from 3-wk-old mice were stained with the following mAb obtained from BD Pharmingen unless otherwise specified: anti-CD4-PE (RM4-5), anti-CD8
-FITC (53-6.7), anti-CD25-FITC (7D4), anti-CD44-PE (IM7), anti-CD4-biotin (RM4-4), anti-CD8
-biotin (53-6.7), anti-CD3
-biotin (500A2), anti-CD11b (Mac-1-
)-biotin (M1/70), anti-NK-1.1-biotin (PK136), anti-Ly-6G (Gr-1), and Ly-6C-biotin (RB6-8C5). Biotinylated Abs were detected by staining with streptavidin-allophycocyanin (Molecular Probes). FACS analysis was performed in the FACS core facility of the M. D. Anderson Cancer Center, Science Park-Research Division (Smithville, TX). Live cells were identified on the basis of forward and side light scatter, and 20,000120,000 events were counted.
To analyze expression of CD25 and CD44 on DN thymocytes, total thymocytes were stained with FITC-conjugated anti-CD25, PE-conjugated anti-CD44, and biotin-conjugated anti-CD3, anti-CD4, anti-CD8, anti-CD11b, anti-NK1.1, anti-Ly6G, and Ly-6C, followed by allophycocyanin-streptavidin. Allophycocyanin-streptavidin-staining cells were gated out to allow analysis of CD25 and CD44 expression on DN thymocytes.
Western blots
Ten micrograms of protein from thymus whole-cell lysates and varying amounts (1030 µg) of protein from different tissues were separated by SDS-PAGE and transferred to nitrocellulose membranes (Schleicher & Schuell Microscience). Western blotting was performed using a SATB1 mouse mAb (BD Transduction Laboratories). Blots were stripped and reprobed with a goat anti-actin polyclonal Ab (Santa Cruz Biotechnology). HRP-conjugated anti-mouse and anti-goat Abs were used with an ECL detection system (Amersham Biosciences) to visualize the proteins. To quantitate the relative amount of SATB1, films were scanned, and the intensity of the bands corresponding to SATB1 and actin was compared using National Institutes of Health image 1.62.
T cell proliferation assay
Spleen cells were isolated by passage through a 70-µm cell strainer (Falcon no. 2350). Following 5 min of incubation with RBC lysis buffer, splenocytes were rinsed twice, then 5 x 104 cells were cultured with 10 ng/ml PMA and 500 ng/ml ionomycin in each well of a 24-well culture plate. Cell numbers were counted at different time points with a hemacytometer.
Statistical analysis
ANOVA was performed to compare the sample means of a set of parameters in groups of mice with six different genotypes (see below). The significance level was set at
= 0.05. When the one-way ANOVA F test was significant (p < 0.05), a pairwise multiple comparison test (Tukey honestly significantly different) was used to study the difference between all possible pairs of means. ANOVA statistical analyses were performed using SYSTAT (version 9.01; SPSS). For Pearson correlation analyses, the significance level was set at
= 0.01, and SPSS (version 10.1.0, 19992000; SPSS) software was used.
| Results |
|---|
|
|
|---|
To produce mice that specifically express SATB1-antisense RNA in T lymphocytes (addressed below), the SATB1 cDNA sequence was cloned in the antisense orientation into a human CD2 minigene-based vector (29) previously shown (31) to confer position-independent, transgene copy number-dependent expression of the included gene in transgenic mice (Fig. 1A). Two founders were identified (Fig. 1B); one of which contained two copies of the transgene with an extra hybridizing band that cosegregated with the band of the expected size. Descendants of this founder were inbred to generate the homozygous SATB1-antisense strain 1 (abbreviated AS1). The second founder carried one copy of the SATB1 transgene, and surprisingly, its homozygous descendants, referred to as the AS2 strain, were found to have kinky tails, likely due to disruption of a nonessential gene involved in axis formation.
|
Although antisense approaches have been used successfully in many systems to down-regulate protein levels in a tissue-specific fashion (32, 33), they generally do not result in complete absence of the protein of interest. This proved to be the case in the present studies as well (see below). Therefore, we crossed AS1 and AS2 mice with heterozygous SATB1-KO mice (28) to try to obtain maximal reduction in thymic SATB1 protein. Progeny were intercrossed to generate mice homozygous for the SATB1-antisense transgene and heterozygous for the SATB1-null allele (referred to as AS1-KO and AS2-KO mice, respectively). We reasoned that reduction in SATB1 expression resulting from the presence of a single functional SATB1 allele (28) would be augmented by the presence of homozygous AS1 or AS2 transgenes.
T lineage specificity of antisense transgene expression generates reduction of SATB1 protein in the thymus
The protein product of the human CD2 minigene has been observed to be expressed uniformly in virtually all thymocytes as well as in peripheral T cells and megakaryocytes (34, 35). As shown in the RT-PCR analyses of Fig. 2A, antisense SATB1 mRNA accumulates predominantly in T cell-containing tissues (thymus, spleen, and lymph nodes). In wild-type mice, SATB1 protein was detected mainly in thymus, spleen, and lymph nodes with a lower level observed in the brain (Fig. 2B). The levels of SATB1 protein relative to actin were determined using National Institutes of Health image analysis. As shown in a representative gel (Fig. 2C) and summarized in Table I, the ratio of SATB1 to actin was reduced substantially in the thymi of experimental mice as compared with wild type. Statistically significant reductions in SATB1:actin ratios were observed in thymocytes of AS1-KO and AS2-KO, as well as in nontransgenic KO mice (p < 0.0001, p = 0.002, and p = 0.01, respectively, in comparison with wild-type mice). All transgenic mice (AS1 or AS2) or mice bearing a SATB1-null allele were significantly smaller than wild-type mice (Table II), but little, if any, difference was seen by 45 wk of age (data not shown). Life spans of transgenic mice were indistinguishable from wild-type mice (data not shown). However, significant reduction in total thymocyte numbers was observed in comparison with wild-type mice for AS2-KO, AS2, and antisense Tg-negative, KO mice (Table II). Neurological defects, such as the incomplete eye opening and the clasping reflex, observed in SATB1-null mice (28), were not observed in the knockdown strains, supporting the view that these symptoms were due to the absence of SATB1 protein from nonthymus tissues, such as brain. The slight reduction (7.1%) of SATB1 protein in the brain of AS1-KO mice (Fig. 2D) is much less than the reduction observed in thymus, spleen, and lymph nodes (58.9, 37.5, and 55.5%, respectively).
|
|
|
The CD4 vs CD8 profiles of thymocytes from representative wild-type, AS1- KO, and AS2-KO mice are shown in Fig. 3. A statistically significant decrease in the percentage of CD8SP thymocytes was observed in mice of these and other genotypes tested when compared with wild type (Table II). The percentage of DN, DP, and CD4SP thymocytes appeared unaffected by the SATB1-antisense transgene or by the SATB1-KO allele (Table II). Reduction in the percentage of CD8SP thymocytes in mice bearing SATB1-antisense transgenes and SATB1-null alleles resulted in a statistically significant increase in thymic CD4SP:CD8SP ratios (Table II). Transgene-negative KO mice barely missed significance at p = 0.058. The CD4 vs CD8 phenotypes in the thymuses and spleens of 2- or 5- to 6-wk-old mice were indistinguishable to those seen at 3 wk of age (data not shown).
|
A Pearson correlation analysis showed that SATB1 protein levels and percentage of CD8SP cells in individual mice showed a significant positive correlation (p = 0.003), whereas SATB1 protein level and the CD4SP:CD8SP ratio exhibited a significant negative correlation (p < 0.0001; Fig. 4). No correlation was observed between the SATB1 protein levels and the percentage of thymic CD4SP cells (data not shown). These results indicate that the percentage of CD8SP cells in the thymus is positively correlated with the amount of SATB1 expression in thymocytes.
|
As shown in Fig. 5, the percentage of CD8SP cells in spleens of AS2-KO mice was reduced significantly relative to wild-type mice, resulting in a significant increase in CD4SP:CD8SP ratio. In lymph nodes, significant increases and decreases in CD4SP and CD8SP cells, respectively, resulted in a significant increase in CD4SP:CD8SP ratio.
|
Because we had hypothesized that SATB1 has an effect on expression of CD8, we tested whether reduction in thymic SATB1 expression resulted in a decrease in the level of surface CD8 as measured by mean fluorescence intensity (MFI). No significant decrease in CD8 MFI on CD8SP thymocytes or any other thymic subpopulations was detected. However, surprisingly, the levels of cell surface CD3 on CD8SP thymocytes of AS1-KO and AS2-KO mice were significantly higher (811 channels) than those of wild-type mice (Fig. 6 and Table III). Examination of CD3 MFI of CD4SP cells and of DP thymocytes revealed no significant differences among AS1-KO, AS2-KO, and wild-type mice. Thus, the effect of SATB1 protein reduction on cell surface CD3 expression appeared to be specific for cells of the CD8SP lineage.
|
|
It is generally accepted that CD3, CD5, and CD69 are up-regulated in CD4SP and CD8SP cells following positive selection and that heat stable Ag is down-regulated (36, 37). Unlike the increase in MFI seen for CD3 on CD8SP thymocytes of AS1-KO and AS2-KO mice, CD3 levels on CD4SP thymocytes of these mice were indistinguishable from those of wild type. Moreover, the patterns of CD5, CD69, and heat stable Ag expression in the CD4SP and DP population did not differ significantly from those of wild-type mice (data not shown). Thus, in the presence of reduced amounts of thymic SATB1 protein, the CD4SP and DP subsets of AS1-KO and AS2-KO mice appear to be indistinguishable from wild type with respect to cell surface maturation.
It is generally agreed that T cell development within the DN population of the thymus progresses in order from CD25CD44+ to CD25+CD44+ to CD25+CD44 to CD25CD44 (38). Previous studies of SATB1-null mice demonstrated multiple defects in T cell development that included a marked reduction in the CD3CD4CD8 triple-negative population and expression of an intermediate level of CD25 on a CD4+CD8+ subset (28). However, FACS analysis of thymocytes showed that none of the four major DN subsets was altered significantly in any of the five genotypes indicated above (data not shown).
SATB1 reduction leads to impaired proliferation of peripheral T cells
To address the mechanism that links reduced SATB1 expression with the reduced thymocyte populations, we used pharmacologic agents (PMA, a protein kinase C activator, and ionomycin, a calcium ionophore) to mimic TCR signaling and to activate T cells. As shown in Fig. 7, there were no obvious differences in cell numbers until after 48 h, when both stimulated AS1-KO and wild-type spleen cells began to proliferate robustly. However, AS1-KO splenocytes achieved only
50% of the number of wild-type cells 72 or 96 h after stimulation. Therefore, peripheral T cells of SATB1-reduced mice have an impaired proliferative response to mitogenic stimuli.
|
| Discussion |
|---|
|
|
|---|
4.5 kb upstream of the mouse CD8
gene, plays a positive role in CD8 expression and development of CD8-positive T cells (16, 17). Consistent with this hypothesis, mice homozygous for SATB1-null alleles lacked both CD8SP and CD4SP T cells and contained thymic anomalies, suggesting a role for SATB1 in normal T cell development (28). However, because these animals died between 2 and 3 wk of age, most likely because of nervous system impairment (28), their abnormal thymus phenotype might be attributed to non-T cell autonomous causes. The present approach was designed to reduce SATB1 expression specifically in T lymphocytes by expressing transgenic SATB1-antisense RNA under the control of a human CD2 cassette. Furthermore, by making the SATB1-antisense transgenic mice heterozygous for a SATB1-null allele, we sought to reduce SATB1 expression in the thymus below a threshold level that might prove to be limiting for normal thymocyte development. This appears to have been successful for both AS1-KO and AS2-KO mice, which demonstrate a significant reduction in the percentage of thymic and peripheral CD8SP cells, thereby increasing the CD4SP:CD8SP ratios (Table II). Some reduction in CD8SP thymocytes was also seen in AS1, AS2, and KO mice, but the level of significance was strongest in AS1-KO and AS2-KO mice. Reduction in mouse weight and thymocyte numbers of mice heterozygous for a SATB1-null allele could reflect nonthymus autonomous effects of SATB1 reduction. However, the reduced mouse weight and numbers of thymocytes also were observed in homozygous AS1 and AS2 that lacked a SATB1-null allele. This raised the possibility that their mixed genetic background had an effect, i.e., mixtures of C57BL/6, DBA/2, and C57BL/6 were used in experimental and wild-type groups, respectively. The fact that the 10th generation of AS1-KO backcrossed to C57BL/6 had indistinguishable body weights from wild-type C57BL/6 mice supports this possibility (data not shown). Alternatively, because SATB1 regulates multiple genes during T cell development, the T cell-specific effect of reduced SATB1 could have an indirect effect, which results in reduction of the body weight and/or the number of thymocytes. Importantly, we observed that the differences in body weight between the transgenic and wild-type mice became invisible by 45 wk of age, while the other phenotypes remained stable.
The basis for the significant increase in surface CD3 expression observed on CD8SP thymocytes of AS1-KO and AS2-KO mice compared with wild-type mice (Fig. 6) is unclear. This difference was confirmed using anti-TCR-
but not anti-TCR-
reagents (data not shown). This enhanced CD3 expression is not seen on CD4SP or DP thymocytes or on CD8SP T cells in lymph nodes and spleens of experimental and wild-type mice. It is possible that the high level of CD3 and 
-TCR results from a perturbation in the requirements for positive selection imposed by reduction of thymic SATB1 protein. Alternatively, it may reflect a role for SATB1 in regulating expression of genes encoding the 
-TCR and/or CD3 components in the thymic CD8SP subset.
In a previous study (7), targeted deletion of a 4-kb HindIII fragment containing L2a and upstream hypersensitive sites within the CD8
enhancer resulted in a reduction of CD8SP thymocytes and in the appearance of a large CD8-negative single positive (SP) thymocyte population. We also found that reduction in thymic SATB1 results in a decrease in CD8SP thymocytes. However, it did not lead to the large degree of variegation in CD8 expression represented by the CD8-negative SP thymocytes observed in the KO report (7). This suggests that reduction of SATB1 may interfere with a late role played by that protein in the maturation of CD8SP thymocytes. The absence of atypical CD8-negative SP thymocytes from AS1-KO and AS2-KO thymuses may indicate that sufficient SATB1 is present to permit a normal DN to DP transition. That the DP thymocytes obtained appear phenotypically normal as opposed to those seen in SATB1-null mice (28) supports a role for SATB1 in this transition. The variegated population of CD8-negative SP thymocytes (7) may result from the deletion within the L2a region of binding sites for other factors, such as Ikaros (39), required for the transition to DP thymocytes.
In the SATB1-reduced mice, we observed reduction exclusively within the CD8SP population. One explanation is that SATB1-reduced CD8SP cells are susceptible to apoptosis. Derepression of apoptosis-related genes in SATB1-null thymocytes, such as PD-1, RIP, and c-myc, may partially explain why SATB1-reduced thymocytes are vulnerable to this mechanism (28). SATB1-deficient CD8SP numbers may be affected by proliferation. In support of this hypothesis, we observed that the proliferative response to PMA plus ionomycin was impaired in SATB1-reduced mature T cells (Fig. 7).
Although these effects may contribute to CD8SP reduction, the mechanism by which SATB1 appears to regulate transcription prompts consideration of its involvement at an earlier commitment step in T cell maturation. SATB1 has been shown to regulate region-specific histone modification (24, 25). SATB1 binds in vitro (17) and in vivo (H. Nie, unpublished results) to the L2a element, and this binding correlates with enhanced CD8
gene expression (17). These data raise the possibility that SATB1 binding to L2a remodels local chromatin structure of the CD8
enhancer. We propose that the consequences for CD8SP maturation provided by this mode of SATB1-L2a interaction are best interpreted in the context of the receptor coreversal model of Brugnera et al. (40). In this model, transcription of CD8 genes is shut off in a post-DP class of CD4SP thymocytes (intermediate thymocytes), and re-establishment of CD8
transcription must occur to complete maturation of CD8SP T cells. We speculate that reinitiation of CD8 transcription requires interaction of SATB1 with the L2a element, thereby establishing the permissive chromatin configuration required for expression of CD8 in mature T cells. Recruitment by SATB1 of the CHRAC/ACF complex (24, 25) to the L2a site of intermediate CD4SP thymocytes at the time of receptor reversal could position nucleosomes in a way favorable for re-expression of CD8
. Reduction in the amount of SATB1 protein at this step might result in failure to reinitiate CD8
expression, and cells bearing MHC class I-specific 
-TCRs may be lost possibly by apoptosis. Further study of the coreceptor reversal hypothesis using thymocytes deficient in SATB1 or containing altered L2a elements should shed light on the role of SATB1 in CD8SP T cell development.
| Disclosures |
|---|
|
|
|---|
| Acknowledgments |
|---|
| Footnotes |
|---|
1 These studies were supported by National Institutes of Health Grant AI47209 (to P.W.T.). ![]()
2 Address correspondence and reprint requests to Dr. Philip W. Tucker, Section of Molecular Genetics and Microbiology, Institute for Cellular and Molecular Biology, University of Texas, 1 University Station A5000, Austin, TX 78712. E-mail address: philtucker{at}mail.utexas.edu ![]()
3 Abbreviations used in this paper: DN, double negative; DP, double positive; MAR, matrix-associated region; KO, knockout; MFI, mean fluorescence intensity; SP, single positive. ![]()
Received for publication June 2, 2003. Accepted for publication February 4, 2005.
| References |
|---|
|
|
|---|
gene expression in subsets of thymocytes and peripheral T cells. Immunity 9:497.[Medline]
resulting from in situ deletion of regulatory sequences. Immunity 16:635.[Medline]
transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers. EMBO J. 16:3987.[Medline]
gene locus during CD4CD8 to CD4+CD8+ thymocyte differentiation. J. Immunol. 160:1256.
enhancer to promote V(D)J recombination. Proc. Natl. Acad. Sci. USA 96:11970.
(Lyt-2) gene transcription. Int. Immunol. 6:1307.
gene locus is regulated by the Ikaros family of proteins. Mol. Cell 10:1403.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |